Sanofi Genzyme announced the start of their phase 4 study (B-CLEAR1, LPS15918), an open-label, multicenter, multinational, randomized, controlled, prospective clinical trial

Sanofi Genzyme announced the start of their phase 4 study (B-CLEAR1, LPS15918), an open-label, multicenter, multinational, randomized, controlled, prospective clinical trial. The primary objective is to assess the reduction of plasma lyso-GL-3 in each group 12 months after randomization. The secondary objectives are to assess the reduction of kidney podocyte GL-3 and endothelial skin cells … Continue reading “Sanofi Genzyme announced the start of their phase 4 study (B-CLEAR1, LPS15918), an open-label, multicenter, multinational, randomized, controlled, prospective clinical trial”

Read More

FIN Newsletter December 2019

Dear All The last Newsletter of 2019! In this edition we continue to share a lot of information and announce a vacancy for the FIN Board. We would also like to draw your attention to our next FIN Expert meeting, next year in Amsterdam.  We look forward to seeing you all at the meeting. FIN … Continue reading “FIN Newsletter December 2019”

Read More

FIN Newsletter October 2019

Dear All We hope your summer was as great as ours was! After relaxing holidays we are now back on track to continue to raise awareness about Fabry Disease! At the beginning of September FIN attended SSIEM in Rotterdam and we also presented our very first FIN booth. We met with colleagues, pharmaceutical partners and … Continue reading “FIN Newsletter October 2019”

Read More

FIN Newsletter June 2019

With the beginning of summer, we are very proud to present you with the latest news from FIN! This newsletter will serve as good reading material during your upcoming vacation! We hope you enjoy reading it! Read more

Read More

FOS Annual Report 2017

Welcome to the 2017 Fabry Outcome Survey (FOS) Annual Report, which provides an overview of FOS as of 5 January 2018. This report includes details of the FOS Steering Committee as well as a summary of patient demographics and the publications that have been developed using the data collected in the registry. FOS (ClinicalTrials.gov identifier: … Continue reading “FOS Annual Report 2017”

Read More

Subscribe to Our Newsletter